

# Raphael Mechoulam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5325895/publications.pdf>

Version: 2024-02-01

68  
papers

7,405  
citations

117625

34  
h-index

88630

70  
g-index

71  
all docs

71  
docs citations

71  
times ranked

6651  
citing authors

#	ARTICLE	IF	CITATIONS
1	N-Oleoyl Glycine and Its Derivatives Attenuate the Acquisition and Expression of Cocaine-Induced Behaviors. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 812-823.	2.9	3
2	A Delightful Trip Along the Pathway of Cannabinoid and Endocannabinoid Chemistry and Pharmacology. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 1-13.	9.4	6
3	Effect of oleoyl glycine and oleoyl alanine on lithium chloride induced nausea in rats and vomiting in shrews. <i>Psychopharmacology</i> , 2022, 239, 377-383.	3.1	2
4	Fenchone Derivatives as a Novel Class of CB2 Selective Ligands: Design, Synthesis, X-ray Structure and Therapeutic Potential. <i>Molecules</i> , 2022, 27, 1382.	3.8	6
5	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal $\delta^9$ -tetrahydrocannabinol-exposed rats. <i>Pharmacological Research</i> , 2021, 164, 105357.	7.1	43
6	Anti-Biofilm Activity of Cannabidiol against <i>Candida albicans</i> . <i>Microorganisms</i> , 2021, 9, 441.	3.6	30
7	Cannabinoid Quinones—A Review and Novel Observations. <i>Molecules</i> , 2021, 26, 1761.	3.8	14
8	N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. <i>Frontiers in Synaptic Neuroscience</i> , 2021, 13, 620145.	2.5	5
9	Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 266-274.	2.9	15
10	Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c-Fos and NeuN expression in the hypothalamus of rats. <i>Journal of Cannabis Research</i> , 2021, 3, 31.	3.2	2
11	Spontaneous and Naloxone-Precipitated Withdrawal Behaviors From Chronic Opiates are Accompanied by Changes in N-Oleoylglycine and N-Oleoylalanine Levels in the Brain and Ameliorated by Treatment With These Mediators. <i>Frontiers in Pharmacology</i> , 2021, 12, 706703.	3.5	9
12	Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. <i>Molecules</i> , 2021, 26, 5601.	3.8	10
13	Beyond THC and Endocannabinoids. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 637-659.	9.4	107
14	Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. <i>Psychopharmacology</i> , 2020, 237, 375-384.	3.1	12
15	Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. <i>Psychopharmacology</i> , 2020, 237, 2621-2631.	3.1	18
16	Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. <i>Psychopharmacology</i> , 2020, 237, 2753-2765.	3.1	11
17	Protective Effects of N-Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1117-1128.	3.5	15
18	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. <i>Biochemical Pharmacology</i> , 2020, 177, 114004.	4.4	36

#	ARTICLE	IF	CITATIONS
19	Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretin-deficient Rats: Preliminary Data. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 18, 705-712.	1.4	10
20	HU-671, a Novel Oleoyl Serine Derivative, Exhibits Enhanced Efficacy in Reversing Ovariectomy-Induced Osteoporosis and Bone Marrow Adiposity. <i>Molecules</i> , 2019, 24, 3719.	3.8	6
21	Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats. <i>Psychopharmacology</i> , 2019, 236, 2623-2633.	3.1	12
22	Effects of cannabidiol in males and females in two different rat models of depression. <i>Physiology and Behavior</i> , 2019, 201, 59-63.	2.1	56
23	Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. <i>Neuropharmacology</i> , 2019, 146, 212-221.	4.1	59
24	<i>Magel2</i> Modulates Bone Remodeling and Mass in Prader-Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 93-105.	2.8	16
25	Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 9-14.	1.7	158
26	Role of CB <sub>2</sub> Receptor in the Recovery of Mice after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 1836-1846.	3.4	25
27	N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. <i>Neuropharmacology</i> , 2019, 148, 320-331.	4.1	37
28	Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 49, 44-50.	2.2	145
29	HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals. <i>Journal of Cellular Physiology</i> , 2018, 233, 530-548.	4.1	61
30	Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT <sub>1A</sub> receptor-mediated suppression of nausea and anxiety in rats. <i>British Journal of Pharmacology</i> , 2018, 175, 100-112.	5.4	53
31	Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. <i>Scientific Reports</i> , 2017, 7, 12064.	3.3	78
32	Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 369-377.	4.8	32
33	Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation. <i>Molecular Medicine</i> , 2016, 22, 136-146.	4.4	56
34	Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. <i>PLoS ONE</i> , 2016, 11, e0158779.	2.5	35
35	HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. <i>Chemical Biology and Drug Design</i> , 2016, 87, 143-153.	3.2	24
36	Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. <i>Molecular Medicine</i> , 2015, 21, 38-45.	4.4	120

#	ARTICLE	IF	CITATIONS
37	Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1770-1775.	2.0	61
38	Effect of the synthetic cannabinoid HU-210 on quorum sensing and on the production of quorum sensing-mediated virulence factors by <i>Vibrio harveyi</i> . <i>BMC Microbiology</i> , 2015, 15, 159.	3.3	23
39	Early phytocannabinoid chemistry to endocannabinoids and beyond. <i>Nature Reviews Neuroscience</i> , 2014, 15, 757-764.	10.2	278
40	The Endocannabinoid System and the Brain. <i>Annual Review of Psychology</i> , 2013, 64, 21-47.	17.7	832
41	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. <i>Neuropharmacology</i> , 2013, 75, 155-163.	4.1	57
42	Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 323-333.	2.4	254
43	Towards a better cannabis drug. <i>British Journal of Pharmacology</i> , 2013, 170, 1363-1364.	5.4	25
44	Cannabidiol - An Innovative Strategy For Graft Versus Host Disease Prevention. <i>Blood</i> , 2013, 122, 3299-3299.	1.4	3
45	Cannabidiol "Recent Advances. <i>Chemistry and Biodiversity</i> , 2007, 4, 1678-1692.	2.1	432
46	Plant cannabinoids: a neglected pharmacological treasure trove. <i>British Journal of Pharmacology</i> , 2005, 146, 913-915.	5.4	94
47	Cannabinoids in Models of Chronic Inflammatory Conditions. <i>Phytochemistry Reviews</i> , 2005, 4, 11-18.	6.5	12
48	Cannabidiol: An Overview of Some Pharmacological Aspects. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 11S-19S.	2.0	385
49	Cannabinoids and brain injury: therapeutic implications. <i>Trends in Molecular Medicine</i> , 2002, 8, 58-61.	6.7	209
50	Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. <i>Chemistry and Physics of Lipids</i> , 2002, 121, 35-43.	3.2	204
51	Suppressors of Cancer Cell Proliferation from Fig ( <i>Ficus carica</i> ) Resin: Isolation and Structure Elucidation. <i>Journal of Natural Products</i> , 2001, 64, 993-996.	3.0	154
52	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. <i>British Journal of Pharmacology</i> , 2001, 134, 845-852.	5.4	945
53	A hunger for cannabinoids. <i>Nature</i> , 2001, 410, 763-765.	27.8	42
54	An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. <i>Nature</i> , 2001, 413, 527-531.	27.8	680

#	ARTICLE	IF	CITATIONS
55	Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. Drug Development Research, 2000, 50, 211-215.	2.9	38
56	Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. , 2000, 50, 211.		1
57	PADMA-28, a traditional tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology, 1999, 7, 47-62.	3.9	34
58	Trick or treat from food endocannabinoids?. Nature, 1998, 396, 636-636.	27.8	101
59	Anandamide may mediate sleep induction. Nature, 1997, 389, 25-26.	27.8	185
60	Todd's achievement. Nature, 1997, 386, 755-755.	27.8	3
61	Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. Pharmaceutical Research, 1996, 13, 469-475.	3.5	14
62	Derivatives of Dexanabinol. I. Water-soluble salts of glycinate esters. Pharmaceutical Research, 1996, 13, 62-69.	3.5	13
63	CANNABINOID ENANTIOMER ACTION ON THE CYTOARCHITECTURE. Cell Biology International, 1996, 20, 147-157.	3.0	23
64	The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Letters, 1995, 375, 143-147.	2.8	170
65	Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase. Journal of Neurochemistry, 1993, 61, 352-355.	3.9	281
66	Subjectively experienced cannabis effects in animals. Drug Development Research, 1989, 16, 385-393.	2.9	11
67	Isolation and structure of .DELTA.+ tetrahydrocannabinol and other neutral cannabinoids from hashish. Journal of the American Chemical Society, 1971, 93, 217-224.	13.7	320
68	The absolute configuration of $\Delta^1$ -tetrahydrocannabinol, the major active constituent of hashish.. Tetrahedron Letters, 1967, 8, 1109-1111.	1.4	185